The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
A phase II, randomized, double‐blind, placebo‐controlled, dose‐ranging study of belimumab in patients with active systemic lupus erythematosus
Open accessAbstract
Objective: To assess the safety, tolerability, biologic activity, and efficacy of belimumab in combination with standard of care therapy (SOC) in patients with active systemic lupus erythematosus (SLE). Methods: Patients with a Safety of Estrogens in Lupus Erythematosus: National Assessment (SELENA) version of the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score ≥4 (n = 449) were randomly assigned to belimumab (1, 4, or 10 mg/kg) or placebo in a 52‐week study. Coprimary end points were the percent change in the SELENA–SLEDAI score at week 24 and the time to first SLE flare. Results: Significant differences between the treatment and placebo groups were not attained for either primary end point, and no dose response was observed. Reductions in SELENA–SLEDAI scores from baseline were 19.5% in the combined belimumab group versus 17.2% in the placebo group. The median time to first SLE flare was 67 days in the combined belimumab group versus 83 days in the placebo group. However, the median time to first SLE flare during weeks 24–52 was significantly longer with belimumab treatment (154 versus 108 days; P = 0.0361). In the subgroup (71.5%) of serologically active patients (antinuclear antibody titer ≥1:80 and/or anti–double‐stranded DNA [anti‐dsDNA] ≥30 IU/ml), belimumab treatment resulted in significantly better responses at week 52 than placebo for SELENA–SLEDAI score (−28.8% versus −14.2%; P = 0.0435), physician's global assessment (−32.7% versus −10.7%; P = 0.0011), and Short Form 36 physical component score (+3.0 versus +1.2 points; P = 0.0410). Treatment with belimumab resulted in a 63–71% reduction of naive, activated, and plasmacytoid CD20+ B cells, and a 29.4% reduction in anti‐dsDNA titers (P = 0.0017) by week 52. The rates of adverse events and serious adverse events were similar in the belimumab and placebo groups. Conclusion: Belimumab was biologically active and well tolerated. The effect of belimumab on the reduction of SLE disease activity or flares was not significant. However, serologically active SLE patients responded significantly better to belimumab therapy plus SOC than to SOC alone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 1982 revised criteria for the classification of systemic lupus erythematosus
Tan, E. M., Cohen, A. S., Fries, J. F., Masi, A. T., Mcshane, D. J., Rothfield, N. F., Schaller, J. G., Talal, N., & Winchester, R. J. (1982) · Arthritis & Rheumatism · doi:10.1002/art.1780251101 · Cited by 14,519
Hochberg, M. C. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400928 · Cited by 11,409
Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project
Ware, J. E., & Gandek, B. (1998) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(98)00081-x · Cited by 2,605
Mice Transgenic for Baff Develop Lymphocytic Disorders along with Autoimmune Manifestations
Mackay, F., Woodcock, S. A., Lawton, P., Ambrose, C., Baetscher, M., Schneider, P., Tschopp, J., & Browning, J. L. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.11.1697 · Cited by 1,480
TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease
Gross, J. A., Johnston, J., Mudri, S., Enselman, R., Dillon, S. R., Madden, K., Xu, W., Parrish-Novak, J., Foster, D., Lofton-Day, C., et al. (2000) · Nature · doi:10.1038/35010115 · Cited by 1,174
Combined Oral Contraceptives in Women with Systemic Lupus Erythematosus
Petri, M., Kim, M. Y., Kalunian, K. C., Grossman, J., Hahn, B. H., Sammaritano, L. R., Lockshin, M., Merrill, J. T., Belmont, H. M., Askanase, A. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051135 · Cited by 1,166
Self-citationBLyS: Member of the Tumor Necrosis Factor Family and B Lymphocyte Stimulator
Moore, P. A., Belvedere, O., Orr, A., Pieri, K., LaFleur, D. W., Feng, P., Soppet, D., Charters, M., Gentz, R., Parmelee, D., et al. (1999) · Science · doi:10.1126/science.285.5425.260 · Cited by 1,144
BCMA Is Essential for the Survival of Long-lived Bone Marrow Plasma Cells
O'Connor, B. P., Raman, V. S., Erickson, L. D., Cook, W. J., Weaver, L. K., Ahonen, C., Lin, L.-L., Mantchev, G. T., Bram, R. J., & Noelle, R. J. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031330 · Cited by 1,128
Cheema, G. S., Roschke, V., Hilbert, D. M., & Stohl, W. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200106)44:6<1313::aid-art223>3.0.co;2-s · Cited by 802
Self-citationCutting Edge: A Role for B Lymphocyte Stimulator in Systemic Lupus Erythematosus
Zhang, J., Roschke, V., Baker, K. P., Wang, Z., Alarcón, G. S., Fessler, B. J., Bastian, H., Kimberly, R. P., & Zhou, T. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.6 · Cited by 734
Cited by
Aringer, M., Costenbader, K., Daikh, D., Brinks, R., Mosca, M., Ramsey‐Goldman, R., Smolen, J. S., Wofsy, D., Boumpas, D. T., Kamen, D. L., et al. (2019) · Arthritis & Rheumatology · doi:10.1002/art.40930 · Cited by 2,677
Self-citationNavarra, S. V., Guzmán, R. M., Gallacher, A. E., Hall, S., Levy, R. A., Jimenez, R. E., Li, E. K.-M., Thomas, M., Kim, H.-Y., León, M. G., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61354-2 · Cited by 2,074
Self-citationFurie, R., Petri, M., Zamani, O., Cervera, R., Wallace, D. J., Tegzová, D., Sanchez-Guerrero, J., Schwarting, A., Merrill, J. T., Chatham, W. W., et al. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30613 · Cited by 1,683
Self-citationAringer, M., Costenbader, K., Daikh, D., Brinks, R., Mosca, M., Ramsey-Goldman, R., Smolen, J. S., Wofsy, D., Boumpas, D. T., Kamen, D. L., et al. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-214819 · Cited by 1,612
Self-citationDevelopment trends for human monoclonal antibody therapeutics
Nelson, A. L., Dhimolea, E., & Reichert, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3229 · Cited by 1,026
Pathogenesis of autoimmune disease
Pisetsky, D. S. (2023) · Nature Reviews Nephrology · doi:10.1038/s41581-023-00720-1 · Cited by 649
Public health importance of triggers of myocardial infarction: a comparative risk assessment
Nawrot, T. S., Perez, L., Künzli, N., Munters, E., & Nemery, B. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62296-9 · Cited by 518
Novel evidence‐based systemic lupus erythematosus responder index
Furie, R. A., Petri, M. A., Wallace, D. J., Ginzler, E. M., Merrill, J. T., Stohl, W., Chatham, W. W., Strand, V., Weinstein, A., Chevrier, M. R., et al. (2009) · Arthritis Care & Research · doi:10.1002/art.24698 · Cited by 490
Self-citationStohl, W., Hiepe, F., Latinis, K. M., Thomas, M., Scheinberg, M. A., Clarke, A., Aranow, C., Wellborne, F. R., Abud‐Mendoza, C., Hough, D. R., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34400 · Cited by 418
Self-citationvan Vollenhoven, R. F., Petri, M. A., Cervera, R., Roth, D. A., Ji, B. N., Kleoudis, C. S., Zhong, Z. J., & Freimuth, W. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-200937 · Cited by 411
Self-citationMerrill, J. T., Burgos‐Vargas, R., Westhovens, R., Chalmers, A., D'Cruz, D., Wallace, D. J., Bae, S. C., Sigal, L., Becker, J. ‐., Kelly, S., et al. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27601 · Cited by 376
Self-citationGordon, C., Amissah-Arthur, M.-B., Gayed, M., Brown, S., Bruce, I. N., D’Cruz, D., Empson, B., Griffiths, B., Jayne, D., Khamashta, M., et al. (2018) · Rheumatology · doi:10.1093/rheumatology/kex286 · Cited by 365
Phage display-derived human antibodies in clinical development and therapy
Frenzel, A., Schirrmann, T., & Hust, M. (2016) · mAbs · doi:10.1080/19420862.2016.1212149 · Cited by 346
Understanding uveitis: The impact of research on visual outcomes
de Smet, M. D., Taylor, S. R. J., Bodaghi, B., Miserocchi, E., Murray, P. I., Pleyer, U., Zierhut, M., Barisani-Asenbauer, T., LeHoang, P., & Lightman, S. (2011) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2011.06.005 · Cited by 340
Mariette, X., Seror, R., Quartuccio, L., Baron, G., Salvin, S., Fabris, M., Desmoulins, F., Nocturne, G., Ravaud, P., & De Vita, S. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-203991 · Cited by 329
New insights into the role of antinuclear antibodies in systemic lupus erythematosus
Pisetsky, D. S., & Lipsky, P. E. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0480-7 · Cited by 303
The role of B cells in atherosclerosis
Sage, A. P., Tsiantoulas, D., Binder, C. J., & Mallat, Z. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0106-9 · Cited by 298
Clearance of pathological antibodies using biomimetic nanoparticles
Copp, J. A., Fang, R. H., Luk, B. T., Hu, C.-M. J., Gao, W., Zhang, K., & Zhang, L. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1412420111 · Cited by 296
Advances in Human B Cell Phenotypic Profiling
Kaminski, D. A., Wei, C., Qian, Y., Rosenberg, A. F., & Sanz, I. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00302 · Cited by 272
B cells as therapeutic targets in SLE
Sanz, I., & Lee, F. E.-H. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.68 · Cited by 261
Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders
Kaegi, C., Wuest, B., Schreiner, J., Steiner, U. C., Vultaggio, A., Matucci, A., Crowley, C., & Boyman, O. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01990 · Cited by 260
Arriens, C., Aberle, T., Carthen, F., Kamp, S., Thanou, A., Chakravarty, E., James, J. A., Merrill, J. T., & Ogunsanya, M. E. (2020) · Lupus Science & Medicine · doi:10.1136/lupus-2019-000360 · Cited by 19
Self-citationPrediction of Lupus Classification Criteria via Generative AI Medical Record Profiling
Nair, S., Lushington, G. H., Purushothaman, M., Rubin, B., Jupe, E., & Gattam, S. (2025) · BioTech · doi:10.3390/biotech14010015 · Cited by 8
Metadata
- Authors
- Wallace, D. J., Stohl, W., Furie, R. A., Lisse, J. R., McKay, J. D., Merrill, J. T., Petri, M. A., Ginzler, E. M., Chatham, W. W., McCune, W. J., Fernandez, V., Chevrier, M. R., Zhong, Z. J., & Freimuth, W. W.
- Venue
- Arthritis Care & Research
- Publisher
- Wiley
- Published
- 2009-08-27
- Volume
- 61
- Issue
- 9
- Pages
- 1168-1178
- ISSN
- 0893-7524 (ISSN-L)
- 1529-0123
- OpenAlex
- W2096286605
- Cited by
- 585
- References
- 37
- FWCI
- 41.64
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.